Ligand Pharmaceuticals Inc

Chart & performance

D1W1MN

P/E

45.17

P/S

20.97

EPS

6.21

Div yield, %

—

Shrs. gr., 5y

4.63%

Rev. gr., 5y

10.39%

Revenues

Net income

CFO

Dividend

Jul 02, 20100.1218 USD/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its comprehensive product line features treatments such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was established in 1987 by Ronald M. Evans and is headquartered in Jupiter, Florida.

URL

https://www.ligand.com/

IPO date

Nov 18, 1992

Employees

Domiciled in

Incorporated in

Valuation

No data to show